Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (41-50 of 284) with videos related to

Pageof 29
Sort By:
Heliyon|September 12, 2024
First line therapy in stage IV BRAF mutated colorectal cancerFausto Petrelli, Maria Antista, Lorenzo Dottorini, et al.
Clinical Colorectal Cancer|February 1, 2022
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survivalDavide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2020
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal CancerChiara Cremolini, Carlotta Antoniotti, Alexander Stein, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 28, 2010
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trialsFotios Loupakis, Emilio Bria, Vanja Vaccaro, et al.
Cancer|October 20, 2011
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategiesFotios Loupakis, Chiara Cremolini, Lisa Salvatore, et al.
The Journal of Molecular Diagnostics : JMD|March 17, 2020
Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System ActivationRiccardo Giannini, Gemma Zucchelli, Mirella Giordano, et al.
Updates in Surgery|May 9, 2023
Colorectal neoplastic emergencies in immunocompromised patients: preliminary result from the Web-based International Register of Emergency Surgery and Trauma (WIRES-T trial)Federico Coccolini, Alessio Mazzoni, Camilla Cremonini, et al.
La Radiologia Medica|November 18, 2025
Attenuation-based estimation of myocardial extracellular volume from ECG-ungated whole-body CT examinations as an early biomarker of chemotherapy-induced cardiotoxicity: preliminary findingsGiovanni Donato Aquaro, Lorenzo Faggioni, Roberto Francischello, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 3, 2023
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancerStefania Crucitta, Martina Ruglioni, Claudia Novi, et al.
Investigational New Drugs|March 1, 2018
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patientsTeresa Di Desidero, Paola Orlandi, Anna Fioravanti, et al.
Pageof 29

Showing results (41-50 of 284) with videos related to

Sort By:
Pageof 29
Heliyon|September 12, 2024
First line therapy in stage IV BRAF mutated colorectal cancerFausto Petrelli, Maria Antista, Lorenzo Dottorini, et al.
Clinical Colorectal Cancer|February 1, 2022
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survivalDavide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2020
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal CancerChiara Cremolini, Carlotta Antoniotti, Alexander Stein, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 28, 2010
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trialsFotios Loupakis, Emilio Bria, Vanja Vaccaro, et al.
Cancer|October 20, 2011
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategiesFotios Loupakis, Chiara Cremolini, Lisa Salvatore, et al.
The Journal of Molecular Diagnostics : JMD|March 17, 2020
Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System ActivationRiccardo Giannini, Gemma Zucchelli, Mirella Giordano, et al.
Updates in Surgery|May 9, 2023
Colorectal neoplastic emergencies in immunocompromised patients: preliminary result from the Web-based International Register of Emergency Surgery and Trauma (WIRES-T trial)Federico Coccolini, Alessio Mazzoni, Camilla Cremonini, et al.
La Radiologia Medica|November 18, 2025
Attenuation-based estimation of myocardial extracellular volume from ECG-ungated whole-body CT examinations as an early biomarker of chemotherapy-induced cardiotoxicity: preliminary findingsGiovanni Donato Aquaro, Lorenzo Faggioni, Roberto Francischello, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 3, 2023
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancerStefania Crucitta, Martina Ruglioni, Claudia Novi, et al.
Investigational New Drugs|March 1, 2018
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patientsTeresa Di Desidero, Paola Orlandi, Anna Fioravanti, et al.
Pageof 29